Valeo Financial Advisors LLC Has $254,000 Position in Milestone Pharmaceuticals Inc. $MIST

Valeo Financial Advisors LLC increased its stake in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 553.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 130,699 shares of the company’s stock after purchasing an additional 110,699 shares during the quarter. Valeo Financial Advisors LLC owned approximately 0.24% of Milestone Pharmaceuticals worth $254,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in MIST. Bay Rivers Group bought a new position in Milestone Pharmaceuticals during the second quarter valued at approximately $28,000. XTX Topco Ltd raised its position in Milestone Pharmaceuticals by 52.7% during the first quarter. XTX Topco Ltd now owns 52,004 shares of the company’s stock valued at $42,000 after acquiring an additional 17,950 shares in the last quarter. Walleye Capital LLC bought a new position in Milestone Pharmaceuticals during the first quarter valued at approximately $74,000. Finally, Propel Bio Management LLC bought a new position in Milestone Pharmaceuticals during the first quarter valued at approximately $1,161,000. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on MIST shares. Wells Fargo & Company started coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, September 11th. They set an “overweight” rating and a $4.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Wednesday. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $4.50.

Milestone Pharmaceuticals Trading Up 4.5%

Shares of MIST stock opened at $2.09 on Friday. Milestone Pharmaceuticals Inc. has a 1 year low of $0.63 and a 1 year high of $2.75. The firm’s fifty day simple moving average is $1.82 and its 200 day simple moving average is $1.57. The firm has a market capitalization of $177.63 million, a P/E ratio of -2.49 and a beta of 0.61.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its earnings results on Tuesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). Equities research analysts anticipate that Milestone Pharmaceuticals Inc. will post -0.62 EPS for the current fiscal year.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.